<?xml version='1.0' encoding='utf-8'?>
<document id="12580990"><sentence text="The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique."><entity charOffset="14-26" id="DDI-PubMed.12580990.s1.e0" text="ketoconazole" /><entity charOffset="69-81" id="DDI-PubMed.12580990.s1.e1" text="fexofenadine" /><pair ddi="false" e1="DDI-PubMed.12580990.s1.e0" e2="DDI-PubMed.12580990.s1.e0" /><pair ddi="false" e1="DDI-PubMed.12580990.s1.e0" e2="DDI-PubMed.12580990.s1.e1" /></sentence><sentence text="To investigate whether the drug-drug interaction between fexofenadine and ketoconazole is localized to efflux transport proteins of the small intestine, and to determine and classify the effective jejunal permeability (Peff) of fexofenadine according to the Biopharmaceutics Classification System (BCS)"><entity charOffset="57-69" id="DDI-PubMed.12580990.s2.e0" text="fexofenadine" /><entity charOffset="74-86" id="DDI-PubMed.12580990.s2.e1" text="ketoconazole" /><entity charOffset="228-240" id="DDI-PubMed.12580990.s2.e2" text="fexofenadine" /><pair ddi="false" e1="DDI-PubMed.12580990.s2.e0" e2="DDI-PubMed.12580990.s2.e0" /><pair ddi="false" e1="DDI-PubMed.12580990.s2.e0" e2="DDI-PubMed.12580990.s2.e1" /><pair ddi="false" e1="DDI-PubMed.12580990.s2.e0" e2="DDI-PubMed.12580990.s2.e2" /><pair ddi="false" e1="DDI-PubMed.12580990.s2.e1" e2="DDI-PubMed.12580990.s2.e1" /><pair ddi="false" e1="DDI-PubMed.12580990.s2.e1" e2="DDI-PubMed.12580990.s2.e2" /></sentence><sentence text="" /><sentence text="Two separate jejunal perfusion experiments were performed using the Loc-I-Gut technique in eight healthy volunteers" /><sentence text=" During treatment 1 (T1), we investigated the acute effect of ketoconazole on the Peff and plasma pharmacokinetics of fexofenadine"><entity charOffset="62-74" id="DDI-PubMed.12580990.s5.e0" text="ketoconazole" /><entity charOffset="118-130" id="DDI-PubMed.12580990.s5.e1" text="fexofenadine" /><pair ddi="false" e1="DDI-PubMed.12580990.s5.e0" e2="DDI-PubMed.12580990.s5.e0" /><pair ddi="false" e1="DDI-PubMed.12580990.s5.e0" e2="DDI-PubMed.12580990.s5.e1" /></sentence><sentence text=" In treatment 2 (T2) we examined the effect of oral pretreatment with ketoconazole (200 mg daily for 5 days) on the same absorption parameters"><entity charOffset="70-82" id="DDI-PubMed.12580990.s6.e0" text="ketoconazole" /></sentence><sentence text=" Each experiment was divided into two periods of 100 min and the jejunal segment was perfused with 93 micro m fexofenadine during both periods"><entity charOffset="110-122" id="DDI-PubMed.12580990.s7.e0" text="fexofenadine" /></sentence><sentence text=" In period 2 of each treatment, fexofenadine was coadministered with 94 micro m ketoconazole"><entity charOffset="32-44" id="DDI-PubMed.12580990.s8.e0" text="fexofenadine" /><entity charOffset="80-92" id="DDI-PubMed.12580990.s8.e1" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.12580990.s8.e0" e2="DDI-PubMed.12580990.s8.e0" /><pair ddi="false" e1="DDI-PubMed.12580990.s8.e0" e2="DDI-PubMed.12580990.s8.e1" /></sentence><sentence text=" The concentrations of fexofenadine in intestinal perfusate and plasma were measured by liquid chromatography with mass detection"><entity charOffset="23-35" id="DDI-PubMed.12580990.s9.e0" text="fexofenadine" /></sentence><sentence text="" /><sentence text="During T1, the mean (+/- s" /><sentence text="d" /><sentence text=") Peff of fexofenadine was low according to the BCS (0"><entity charOffset="10-22" id="DDI-PubMed.12580990.s13.e0" text="fexofenadine" /><entity charOffset="48-51" id="DDI-PubMed.12580990.s13.e1" text="BCS" /><pair ddi="false" e1="DDI-PubMed.12580990.s13.e0" e2="DDI-PubMed.12580990.s13.e0" /><pair ddi="false" e1="DDI-PubMed.12580990.s13.e0" e2="DDI-PubMed.12580990.s13.e1" /></sentence><sentence text="11 +/- 0" /><sentence text="11 and 0" /><sentence text="04 +/- 0" /><sentence text="13 x 10(-4) cm s(-1) in periods 1 and 2, respectively), and the coadministration of ketoconazole in period 2 had no significant acute effect on Peff (95% confidence interval (CI) on the difference -0"><entity charOffset="84-96" id="DDI-PubMed.12580990.s17.e0" text="ketoconazole" /></sentence><sentence text="37, 0" /><sentence text="51)" /><sentence text=" After pretreatment with ketoconazole (T2), the jejunal Peff of fexofenadine increased to 0"><entity charOffset="25-37" id="DDI-PubMed.12580990.s20.e0" text="ketoconazole" /><entity charOffset="64-76" id="DDI-PubMed.12580990.s20.e1" text="fexofenadine" /><pair ddi="false" e1="DDI-PubMed.12580990.s20.e0" e2="DDI-PubMed.12580990.s20.e0" /><pair ddi="false" e1="DDI-PubMed.12580990.s20.e0" e2="DDI-PubMed.12580990.s20.e1" /></sentence><sentence text="29 +/- 0" /><sentence text="47 and 0" /><sentence text="22 +/- 0" /><sentence text="31 x 10-4 cm s(-1) in both periods 1 and 2, respectively, but the change was not statistically significant when compared with T1 (95% CI on the difference -0"><entity charOffset="134-136" id="DDI-PubMed.12580990.s24.e0" text="CI" /></sentence><sentence text="62, 0" /><sentence text="27 for T1 0-100 min vs T2 0-100 min; -0" /><sentence text="54, 0" /><sentence text="34 for T1 0-100 min vs T2 100-200 min)" /><sentence text=" Fexofenadine plasma AUC from 0-100 mg showed no significant difference after pretreatment with ketoconazole (55 +/- 101 and 51 +/- 33 micro g ml(-1) min(-1) respectively; 95% CI on the difference -108, 115)"><entity charOffset="1-13" id="DDI-PubMed.12580990.s29.e0" text="Fexofenadine" /><entity charOffset="96-108" id="DDI-PubMed.12580990.s29.e1" text="ketoconazole" /><entity charOffset="176-178" id="DDI-PubMed.12580990.s29.e2" text="CI" /><pair ddi="false" e1="DDI-PubMed.12580990.s29.e0" e2="DDI-PubMed.12580990.s29.e0" /><pair ddi="false" e1="DDI-PubMed.12580990.s29.e0" e2="DDI-PubMed.12580990.s29.e1" /><pair ddi="false" e1="DDI-PubMed.12580990.s29.e0" e2="DDI-PubMed.12580990.s29.e2" /><pair ddi="false" e1="DDI-PubMed.12580990.s29.e1" e2="DDI-PubMed.12580990.s29.e1" /><pair ddi="false" e1="DDI-PubMed.12580990.s29.e1" e2="DDI-PubMed.12580990.s29.e2" /></sentence><sentence text=" Total plasma AUC (0-720 min) was 318 +/- 426 and 426 +/- 232 ng ml(-1) min in T1 and T2, respectively (95% CI on the difference -622, 405)"><entity charOffset="108-109" id="DDI-PubMed.12580990.s30.e0" text="CI" /></sentence><sentence text="" /><sentence text="No significant effect of acute coadministration or pretreatment with ketoconazole on the in vivo intestinal absorption of fexofenadine was detected in this study"><entity charOffset="69-81" id="DDI-PubMed.12580990.s32.e0" text="ketoconazole" /><entity charOffset="122-134" id="DDI-PubMed.12580990.s32.e1" text="fexofenadine" /><pair ddi="false" e1="DDI-PubMed.12580990.s32.e0" e2="DDI-PubMed.12580990.s32.e0" /><pair ddi="false" e1="DDI-PubMed.12580990.s32.e0" e2="DDI-PubMed.12580990.s32.e1" /></sentence><sentence text="" /></document>